Clinicians’ Guide to the Use of Fecal Calprotectin to Identify and Monitor Disease Activity in Inflammatory Bowel Disease | Zendy

Brian Bressler | Zendy; Remo Panaccione | Zendy; Richard N. Fedorak | Zendy; Ernest G. Seidman | Zendy

Open Access

Clinicians’ Guide to the Use of Fecal Calprotectin to Identify and Monitor Disease Activity in Inflammatory Bowel Disease

Author(s) -

Brian Bressler,

Remo Panaccione,

Richard N. Fedorak,

Ernest G. Seidman

Publication year - 2015

Publication title -

canadian journal of gastroenterology and hepatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.921

H-Index - 65

eISSN - 2291-2797

pISSN - 2291-2789

DOI - 10.1155/2015/852723

Subject(s) - medicine , calprotectin , inflammatory bowel disease , biomarker , disease , colonoscopy , inflammation , ulcerative colitis , gastroenterology , faecal calprotectin , crohn's disease , immunology , colorectal cancer , cancer , biochemistry , chemistry

Objective monitoring of the severity of inflammation in patients with inflammatory bowel disease (IBD) is an essential part of disease management. However, repeat endoscopy to define extent and severity of inflammation is not practical. Fecal calprotectin (FC) is a biomarker that can be used as a surrogate test to distinguish inflammatory from noninflammatory gastrointestinal disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research